KEY POINTS
- F-SHARP was a multi-institutional phase I/II clinical trial evaluating dose-escalated focal salvage high-dose-rate brachytherapy (DE-fsHDR) for intraprostatic recurrence following definitive radiotherapy for localized prostate cancer. The study enrolled 62 patients, with the primary objective of assessing acute CTCAE v4.03 grade ≥3 gastrointestinal and genitourinary toxicity.
- Participants received focal salvage HDR brachytherapy delivering up to 30 Gy in one or two fractions. Twenty-four patients received a single-fraction treatment, while 38 received two fractions. Secondary endpoints included all-grade treatment-related toxicity, quality of life measured using EPIC-26 and the International Prostate Symptom Score, biochemical and radiographic progression, local recurrence, metastasis and survival.
- At a median follow-up of 39.4 months, no acute grade 3 toxicity was observed in the 62 treated patients. Two patients (3.2%) developed late grade 3 toxicity, providing an encouraging safety signal for focal salvage treatment in a previously irradiated prostate, although the available abstract does not specify the affected organs, duration or interventions required for these late events.
- Patient-reported quality-of-life changes did not meet predefined criteria for a minimal clinically important difference. This finding suggests that substantial group-level deterioration in the measured EPIC-26 and urinary symptom domains was not detected, but the available report does not provide detailed longitudinal domain scores, individual symptom trajectories or the proportion experiencing clinically important deterioration.
- At three years, estimated biochemical progression-free survival was 62.7%, radiographic progression-free survival was 67.5%, local recurrence-free survival was 73.0%, and metastasis-free survival was 85.9%. No statistically significant differences were reported between the one- and two-fraction groups (all p>0.05), although the nonrandomized treatment allocation and limited patient numbers prevent conclusions about equivalence between fractionation approaches.
- A genomic classifier based on a clinical-grade transcriptomic assay was evaluated in 31 patients, approximately half the treatment cohort. Higher genomic classifier scores were associated with worse biochemical progression-free, radiographic progression-free, local recurrence-free and metastasis-free survival, suggesting that tumor biology may identify patients less likely to achieve durable control from focal salvage treatment alone.
- Among patients with genomic classifier scores >0.85 (n=4), all experienced biochemical, local and metastatic recurrence during follow-up. This striking association is based on only four patients and should be interpreted as exploratory, not a validated risk threshold. The absence of a randomized comparator, limited biomarker availability and lack of detailed stratified outcome estimates in the supplied abstract restrict conclusions about which patients require systemic or local treatment intensification.
CLINICAL TAKEAWAY
Dose-escalated focal salvage HDR brachytherapy demonstrated encouraging acute tolerability and three-year disease-control outcomes in patients with intraprostatic recurrence after definitive radiation. Genomic classifier scores may help identify individuals at higher risk of progression after focal salvage treatment, but this early-phase evidence does not establish the optimal fractionation schedule or justify genomic-guided treatment intensification without prospective validation.